Novel peripheral blood mononuclear cell mRNA signature for IFN-beta therapy responsiveness prediction in multiple sclerosis

References

• Galea I, Ward-Abel N, Heesen C. Relapse in multiple sclerosis. BMJ. 2015;350(apr14 8):1h1765.
   Google Scholar
• Kalincik T. Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology. 2015;44(4):199–214.
   PubMed Web of Science ®Google Scholar
• Freeman L, Longbrake EE, Coyle PK, et al. High-efficacy therapies for treatment-Naïve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285–1299.
   PubMed Web of Science ®Google Scholar
• Li H, Hu F, Zhang Y, et al. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 2020;267(12):3489–3498.
   PubMed Web of Science ®Google Scholar
• Huber AK, Duncker PC, Irani DN. The conundrum of interferon-β non-responsiveness in relapsing-remitting multiple sclerosis. Cytokine. 2015;74(2):228–236.
   PubMed Web of Science ®Google Scholar
• Haji Abdolvahab M, Mofrad MR, Schellekens H. Interferon beta: from molecular level to therapeutic effects. Int Rev Cell Mol Biol. 2016;326:343–372.
   PubMed Web of Science ®Google Scholar
• Hegen H, Millonig A, Bertolotto A, et al. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler. 2014;20(5):577–587.
   PubMed Web of Science ®Google Scholar
• Dujmovic I, Hegen H, Paz P, et al. Persistency of neutralizing anti-interferon-β antibodies in patients with multiple sclerosis treated with subcutaneous interferon-β depends on antibody titers, IgG subclasses, and affinity maturation. J Interferon Cytokine Res. 2017;37(7):317–324.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Coyle PK, Hellwig K, et al. Twenty years of subcutaneous interferon-Beta-1a for multiple sclerosis: contemporary perspectives. Neurol Ther. 2024;13(2):283–322.
   PubMed Web of Science ®Google Scholar
• Ciplea AI, Langer-Gould A, Stahl A, et al. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: one-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e757.
   PubMed Web of Science ®Google Scholar
• Hellwig K, Geissbuehler Y, Sabidó M, et al. European interferon-beta pregnancy study group. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European interferon-beta pregnancy registry. J Neurol. 2020;267(6):1715–1723.
   PubMed Web of Science ®Google Scholar
• Paap BK, Hundeshagen A, Hecker M, et al. An inventory of short term and long term changes in gene expression under interferon β treatment of relapsing remitting MS patients. CPD. 2012;18(29):4475–4484.
   Google Scholar
• Jin T, Wang C, Tian S. Feature selection based on differentially correlated gene pairs reveals the mechanism of IFN-β therapy for multiple sclerosis. PeerJ. 2020;8:e8812.
   PubMed Web of Science ®Google Scholar
• Croze E. Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):743–749.
   PubMed Web of Science ®Google Scholar
• Baranzini SE. Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis. Autoimmunity. 2006;39(8):651–662.
   PubMed Web of Science ®Google Scholar
• Matas E, Bau L, Martínez-Iniesta M, et al. Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients. J Neurol. 2016;263(4):722–729.
   PubMed Web of Science ®Google Scholar
• Malhotra S, Río J, Urcelay E, et al. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain. 2015;138(3):644–652.
   PubMedGoogle Scholar
• Pietrzak A, Kalinowska-Łyszczarz A, Osztynowicz K, et al. A long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing- remitting multiple sclerosis. Adv Clin Exp Med. 2020;29(7):841–851.
   PubMed Web of Science ®Google Scholar
• Singh MK, Scott TF, LaFramboise WA, et al. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci. 2007;258(1–2):52–59.
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Datta P, Larsen J, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler. 2008;14(5):615–621.
   PubMed Web of Science ®Google Scholar
• Rio J, Rovira A, Blanco Y, et al. Respuesta al tratamiento con interferon beta en pacientes con esclerosis multiple. Validacion del Rio Score [Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score]. Rev Neurol. 2016;63(4):145–150.
   PubMedGoogle Scholar
• Zhang M, Wang X, Chen X, et al. Novel immune-related gene signature for risk stratification and prognosis of survival in lower-Grade glioma. Front Genet. 2020;11(1):363.
   PubMedGoogle Scholar
• Xu X, Wu Y, Jia G, et al. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer. J Ovarian Res. 2023;16(1):5.
   PubMed Web of Science ®Google Scholar
• Fukushima A, Sugimoto M, Hiwa S, et al. Elastic net-based prediction of IFN-β treatment response of patients with multiple sclerosis using time series microarray gene expression profiles. Sci Rep. 2019;9(1):1822.
   PubMedGoogle Scholar
• Gelati M, Corsini E, Dufour A, et al. Transmigration of PBMNCs from beta-IFN-1b-treated MS patients: a one-year longitudinal study. Autoimmunity. 2001;33(4):275–283.
   PubMed Web of Science ®Google Scholar
• Garg N, Weinstock-Guttman B, Bhasi K, et al. An association between autoreactive antibodies and anti-interferon-β antibodies in multiple sclerosis. Mult Scler. 2007;13(7):895–899.
   PubMedGoogle Scholar
• Pachner AR, Dail D, Pak E, et al. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol. 2005;166(1–2):180–188.
   PubMed Web of Science ®Google Scholar
• Goertsches RH, Hecker M, Koczan D, et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics. 2010;11(2):147–161.
   PubMed Web of Science ®Google Scholar
• Hecker M, Goertsches RH, Fatum C, et al. Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment. Pharmacogenomics J. 2012;12(2):134–146.
   PubMed Web of Science ®Google Scholar
• Hecker M, Hartmann C, Kandulski O, et al. Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients’ individual gene expression in peripheral blood. Mol Neurobiol. 2013;48(3):737–756.
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3(1):3–25.
   Google Scholar
• Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216–W221.
   PubMed Web of Science ®Google Scholar
• Steinman L, Fox E, Hartung HP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704–714.
   PubMed Web of Science ®Google Scholar
• Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782.
   PubMed Web of Science ®Google Scholar
• Serrano-Fernández P, Möller S, Goertsches R, et al. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity. 2010;43(2):172–178.
   PubMed Web of Science ®Google Scholar
• Annibali V, Di Giovanni S, Cannoni S, et al. Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis. Autoimmunity. 2007;40(1):16–22.
   PubMed Web of Science ®Google Scholar
• Schmeisser H, Bekisz J, Zoon KC. New function of type I IFN: induction of autophagy. J Interferon Cytokine Res. 2014;34(2):71–78.
   PubMed Web of Science ®Google Scholar
• Ejlerskov P, Rubinsztein DC, Pocock R. IFNB/interferon-β regulates autophagy via a MIR1-TBC1D15-RAB7 pathway. Autophagy. 2020;16(4):767–769.
   PubMed Web of Science ®Google Scholar
• Sirisena DMKP, Tharuka MDN, Liyanage DS, et al. An interferon-induced GTP-binding protein, Mx, from the redlip mullet, liza haematocheila: deciphering its structural features and immune function. Fish Shellfish Immunol. 2020;96:279–289.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Asano A, Okano S, et al. Intracellular localization and antiviral property of canine Mx proteins. J Interferon Cytokine Res. 2005;25(3):169–173.
   PubMed Web of Science ®Google Scholar
• Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009;73(5):372–377.
   PubMed Web of Science ®Google Scholar
• Hemmer B, Berthele A. Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis? Nat Clin Pract Neurol. 2012;19(10):1311–1317.
   Google Scholar
• Jensen PE, Sellebjerg F, Søndergaard HB, et al. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients. Euro J of Neurology. 2012;19(10):1311–1317.
   PubMed Web of Science ®Google Scholar
• Jiang X, Yin L, Zhang N, et al. Bisphenol a induced male germ cell apoptosis via IFN β-XAF1-XIAP pathway in adult mice. Toxicol Appl Pharmacol. 2018;355:247–256.
   PubMed Web of Science ®Google Scholar
• Jeong SI, Kim JW, Ko KP, et al. XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis. Cell Death Dis. 2018;9(8):806.
   PubMedGoogle Scholar
• Talebizadeh Z, Simon SD, Butler MG. X chromosome gene expression in human tissues: male and female comparisons. Genomics. 2006;88(6):675–681.
   PubMed Web of Science ®Google Scholar
• Fang H, Disteche CM, Berletch JB. X inactivation and escape: epigenetic and structural features. Front Cell Dev Biol. 2019;7:219.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Shao M, Dai X, et al. Identification of diagnostic ­biomarkers in systemic lupus erythematosus based on ­bioinformatics analysis and machine learning. Front Genet. 2022;13:865559.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Sakai J, Okada AA, et al. Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis. Graefes Arch Clin Exp Ophthalmol. 2002;240(4):314–321.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Warner BM, Odani T, et al. LAMP3 induces apoptosis and autoantigen release in Sjögren’s syndrome patients. Sci Rep. 2020;10(1):15169.
   PubMed Web of Science ®Google Scholar
• Magyari M, Koch-Henriksen N, Laursen B, et al. Gender effects on treatment response to interferon-beta in multiple sclerosis. Acta Neurol Scand. 2014;130(6):374–379.
   PubMed Web of Science ®Google Scholar
• Johansson P, Corripio-Miyar Y, Wang T, et al. Characterisation and expression analysis of the rainbow trout (Oncorhynchus mykiss) homologue of the human dendritic cell marker CD208/ lysosomal associated membrane protein 3. Dev Comp Immunol. 2012;37(3–4):402–413.
   PubMed Web of Science ®Google Scholar